NK Cell Immunotherapy

A physician-led treatment program for select cancer patients, built on autologous NK cell expansion and rigorous clinical oversight.

Is This an Approach You Should Consider?

NK cell immunotherapy is not appropriate for every cancer patient, and we do not present it as such. It is a structured, physician-led option that may be appropriate for a specific subset of patients — those with solid tumors who meet eligibility criteria established through individual clinical review.

If you are a patient or family member researching immunotherapy as an additional option after conventional treatment, or between treatment phases, this page is designed to give you an honest, complete picture of what this program involves, who it may benefit, and what you should understand before making any decisions.

The right next step is a medical review — not a financial commitment. That review is the only way to know whether this program may be suitable for your specific case.

What Is NK Cell Immunotherapy?

Natural killer (NK) cells are a type of lymphocyte — a white blood cell central to the body's immune surveillance system. NK cells are notable for their ability to recognize and respond to abnormal cells without prior sensitization, a characteristic that has attracted sustained research interest in the context of cancer.

In an autologous NK cell program, cells are collected from the patient, expanded in a clinical-grade laboratory environment, and reintroduced as part of a structured treatment protocol. Using the patient's own cells avoids many of the compatibility concerns associated with donor-sourced cell therapies.

Who May Be a Candidate

May Be Considered

  • Adults diagnosed with a solid tumor malignancy
  • Patients who have completed or are between conventional treatment phases
  • Those in stable enough condition to travel and undergo treatment
  • Individuals whose case has been reviewed and accepted through our medical review process
  • Patients who understand and accept the current evidence landscape for dendritic cell therapy

Likely Not a Candidate

  • Patients with blood cancers (our program focuses on solid tumors)
  • Individuals in acute or critical medical condition requiring immediate intervention
  • Those who are not willing or able to travel to Mexico for the program
  • Patients seeking a guarantee of outcomes — which no responsible provider can offer
  • Cases where our physician team's review determines that the risk profile is not suitable

The only definitive way to determine candidacy is through physician review of your specific case. General criteria are helpful for orientation — they are not a determination.

Take the First Step

Submit your case for physician review. There is no cost to the initial review and no obligation to proceed. The review is the only way to get an honest, clinical answer about whether this program may be appropriate for you.

Request Medical Review Cost Information

Common Questions

Frequently Asked Questions

We ask every prospective patient to engage seriously with the following before proceeding.

NK cell immunotherapy is not an established first-line treatment for any solid tumor. It is a physician-evaluated additional option, offered to select patients who meet clinical criteria.
Individual responses to any treatment vary. We do not make promises about outcomes and we communicate this clearly before any commitment is made.
No patient receives treatment without a formal physician review. This is a requirement, not a formality — it protects both the patient and the integrity of our program.
Initial programs typically require 1 to 3 weeks on-site in Mexico. Patients must be in a condition to travel and to participate in the program as structured.

Still have questions?

View All FAQs

Ready to evaluate your case?

Request a Confidential Medical Review